Docoh
Loading...

DFFN Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Company profile

Ticker
DFFN
Exchange
CEO
Robert J. Cobuzzi
Employees
Incorporated
Location
Fiscal year end
Former names
FERIS INTERNATIONAL, INC., RestorGenex Corp, Stratus Media Group, Inc, TITAN MOTORCYCLE CO OF AMERICA INC
SEC CIK
IRS number
300645032

DFFN stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 Nov 20
6 Mar 21
31 Dec 21
Quarter (USD)
Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 21.91M 21.91M 21.91M 21.91M 21.91M 21.91M
Cash burn (monthly) 1.22M (positive/no burn) 1.76M 1.24M 1.17M 1.03M
Cash used (since last report) 6.32M n/a 9.13M 6.47M 6.08M 5.33M
Cash remaining 15.59M n/a 12.78M 15.44M 15.83M 16.58M
Runway (months of cash) 12.8 n/a 7.3 12.4 13.5 16.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Mar 21 William Karl Hornung Stock Option Common Stock Grant Aquire A No No 1.11 80,069 88.88K 80,069
1 Mar 21 William Karl Hornung Stock Option Common Stock Grant Aquire A No No 1.11 122,771 136.28K 122,771
1 Mar 21 William Robert Elder Stock Option Common Stock Grant Aquire A No No 1.11 62,522 69.4K 62,522
1 Mar 21 William Robert Elder Stock Option Common Stock Grant Aquire A No No 1.11 87,684 97.33K 87,684
1 Mar 21 Christopher D Galloway Stock Option Common Stock Grant Aquire A No No 1.11 81,537 90.51K 81,537
1 Mar 21 Christopher D Galloway Stock Option Common Stock Grant Aquire A No No 1.11 27,180 30.17K 27,180
1 Mar 21 Cobuzzi Robert Joseph Jr. Stock Option Common Stock Grant Aquire A No No 1.11 161,139 178.86K 161,139
1 Mar 21 Cobuzzi Robert Joseph Jr. Stock Option Common Stock Grant Aquire A No No 1.11 53,713 59.62K 53,713
17 Nov 20 William Robert Elder Common Stock Buy Aquire P No No 0.63 5,000 3.15K 15,000
16 Nov 20 William Robert Elder Common Stock Buy Aquire P No No 0.67 10,000 6.7K 10,000
4.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 21 25 -16.0%
Opened positions 5 8 -37.5%
Closed positions 9 7 +28.6%
Increased positions 3 6 -50.0%
Reduced positions 4 7 -42.9%
13F shares
Current Prev Q Change
Total value 3.86M 4.31M -10.5%
Total shares 4.85M 5.12M -5.2%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Renaissance Technologies 2.83M $2.25M -5.2%
BLK Blackrock 830.47K $660K 0.0%
Vanguard 393.23K $312K +11.6%
Geode Capital Management 255.69K $203K 0.0%
NTRS Northern Trust 107.89K $86K -1.3%
Two Sigma Investments 106.34K $85K NEW
Fan Yu 89.85K $71K NEW
Two Sigma Advisers 69.7K $55K NEW
Raymond James Financial Services Advisors 40K $32K 0.0%
Advisor 29.48K $24K -8.2%
Largest transactions
Shares Bought/sold Change
VIRT Virtu Financial 0 -155.83K EXIT
Renaissance Technologies 2.83M -155.81K -5.2%
Two Sigma Investments 106.34K +106.34K NEW
GS Goldman Sachs 0 -98.12K EXIT
Fan Yu 89.85K +89.85K NEW
Two Sigma Advisers 69.7K +69.7K NEW
Citadel Advisors 0 -52.66K EXIT
Vanguard 393.23K +40.95K +11.6%
HCR Wealth Advisors 0 -30K EXIT
Squarepoint Ops 0 -24.16K EXIT

Financial report summary

?
Competition
Curis
Management Discussion
  • We recognized $3.1 million in R&D expenses during the three months ended September 30, 2020 compared to $1.7 million during the three months ended September 30, 2019. A significant portion of this increase was attributable to R&D expenses related to the 100-303 COVID Trial initiated in September 2020 and our related ramp-up, including a $0.4 million increase in manufacturing costs and a $1.0 million increase in clinical trial and other R&D expenses. The overall increase in R&D expense also includes a $0.1 million increase in costs associated with the PHAST Trial, primarily costs related to winding down the trial. These increases in R&D expenses were offset in part by a $0.1 million decrease in R&D related salaries, wages and stock-based compensation expense.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accomplish, adjudication, adjunctive, adjunctively, administered, afflicted, Affordable, air, allosteric, ambulance, analyzed, appointed, arrangement, artery, ascending, attempt, avoiding, belief, Bioconnect, biopharmaceutical, Biotech, blocked, bonding, breakdown, breathing, broad, Bucharest, cell, Christopher, claudication, Cobuzzi, complex, complicated, complicating, complication, concept, Conference, confirmed, contributor, Corona, counsel, coupled, COVID, CRO, cumulative, daily, dense, detail, die, director, Education, efficient, Elder, employee, encountered, endpoint, energy, enhance, equipment, evenly, eventually, excessive, expansion, expediting, experimental, explained, explicitly, extension, extracorporeal, factor, final, frequency, fully, Galloway, greater, HC, heading, high, Hollingsworth, hydrogen, hyperoxia, identification, implied, infiltration, innovative, intermittent, intractable, invalidation, ischemia, Jane, knowledge, leadership, Litigation, lt, matrix, membrane, metabolic, modification, NOL, onset, opportunistic, ordinary, Orphan, outsource, oversee, ownership, oximetry, peripheral, persistence, pharmacodynamic, pharmacokinetic, political, postponed, predecessor, preferentially, presidential, Prevention, prioritizing, proceed, produce, progressing, promulgated, proof, prospectively, publicly, pulse, put, quantify, Reconciliation, red, Reform, regimen, relevant, remeasured, repeal, replacement, resignation, responded, retirement, Robert, Romania, room, Secondary, separation, sequential, Showcase, stockholder, streamline, subgroup, subsidized, successfully, summer, supplemental, taxable, team, tolerability, tolerable, topline, toxicity, Trail, unamended, Union, unknown, variety, ventilation, vessel, virtual, warrent, water, William, wind, winding
Removed: administrative, assumed, bring, bulk, cardiovascular, cellular, Codification, commencement, commercial, competing, continuing, cooperation, criteria, crocetinate, cut, dependent, deprivation, DSMB, emergency, entering, exploring, forward, growth, hire, improving, inaccurate, inherent, label, met, move, multiforme, NDA, neurodegenerative, omitted, open, permission, practice, PreHospital, promote, protect, randomization, ranging, reader, safely, scope, selectively, sodium, spend, strong, survival, test, tested, transcrocetinate, treated, tumor, type, UCLA, University, unmet, untreated, utility